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Abstract 
BACKGROUND: Basal cell carcinomas (BCC) located in the sun-exposed regions are a serious therapeutic 
challenge. Therefore early diagnosis and adequate therapy should be of a high priority for every dermatologic 
surgeon.  
CASE PRESENTATION: We are presenting a patient with multiple BCCs, located on the area of the scalp, who 
had been treated several years ago with electrocautery and curettage after histopathological verification. 
However, the last few years the tumours have advanced, infiltrating firstly the tabula external and a year later the 
tabula interna of the cranium. A computed -tomography (CT) imaging and radiography of the skull were performed 
to reveal the definite tumour localisation, needed for planning an one - step surgical intervention. Both of the 
instrumental examinations confirmed the existence of osteolytic tumour lesions. Craniotomy with precise removal 
of the BCCs infiltrating the cranial bone in all of its thickness was performed. Partial resection of dura mater was 
also performed also because intraoperative findings established the involvement of the dura. Histopathological 
verification revealed bone and dural invasion with clean resection margins. The bone defect was recovered with 
hydroxyapatite cement. Reconstruction as the shape of the skull was carefully modified and adapted to its initial 
size and form. Layered closure of the skin and soft tissues were performed after the complete removal of the 
BCCs. The postoperative period had no serious complications. 
CONCLUSION: Precisely managed therapy of BCC is curative in most of the cases as it ensures good prognosis 
for the patient. 
 
 
 
 
 
Introduction 
 
Basal cell carcinoma (BCC) is non -
melanocytic skin epithelial tumour arising from the 
basal layer cells of the epidermis [1]. In the last few 
years, world statistics show rapidly increasing 
incidence rate as the lifetime risk is reaching nearly 
30% [2]. Although BCC does not demonstrate 
significant metastatic tendency, its local destructive 
and infiltrative nature, as well as its tendency to 
receive turns, is into a serious medical problem, which 
should not be neglected [3]. Since exposure to UV - 
radiation is the main etiological factor of BCC, 
prevalent locations of the lesions are the face and the 
head, and scalp is the most commonly affected area 
[4]. Behind the acronym “SCALP” stands its five 
structural layers - skin, subcutaneous tissue, 
aponeurosis, loose areolar tissue, and periosteum. In 
cases of highly progressive local invasion, the tumour 
process infiltrates galea aponeurotica, periosteum, 
calvaria, superficial and deep layers of dura mater and 
the underlying brain [5] successively. At this stage, the 
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invasion of deeper tissues compromises treatment 
opportunities for achieving an optimal therapeutic 
result; it reflects on the long-time survival of the 
patient and increases healthcare costs as well [6].  
Therefore, precise diagnostic approach and 
accurate therapeutic strategies are mandatory for 
prevention of any further complications which at a 
later stage could be fatal.  
 
 
Case report 
 
We present a 68 – year - old patient with 
multiple primary infiltrative BCCs in the scalp area 
initially treated 14 years ago with superficial contact X-
ray therapy, end does 60 greys, followed by 
electrocautery (x2) several years later (Figure 1a). He 
presented to the dermatologic policlinic for diagnosis 
and therapy of two newly - formed pigmented lesions 
located in the left parietal region. Also, two chronic 
non - healing ulcerative wounds were observed in the 
same area which had occurred 6 years ago according 
to anamnestic data. An uncomfortable, itchy, burning 
sensation in the region was reported as a subjective 
complaint (Figure 1a - d). Somatic and neurological 
status as well as paraclinical assessment and chest 
X-ray examinations did not show any abnormalities. 
Profile radiography of the skull detected two osteolytic 
zones with irregular borders in the parietal region; no 
structural changes were observed.  
 
Figure 1: а) Clinical suspicion of 2 pigmented basal cell carcinomas, located 
next to the area of 2 ulcerated lesions. The ulcerated lesions are histologically 
confirmed as basal cell carcinomas; b) One year later wide expansion of the 
ulcerative lesions is observed with the addition of pain and bleeding; c) 4 
months later 2 hyperkeratotic tumor formations with blood/yellow discharge 
have appeared; d - f) CT - examination of the lesions revealed progression in 
depth and involvement of tabula interna of the tumor process (one year 
earlier CT - examination detected tumor infiltration only in tabula external) 
 
Cranial computed - tomography (CT) 
examination performed in June 2017 revealed two 
deformities in the form of tumour-mediated osteolysis, 
affecting the diploe of the tabula externa on the left 
parietal and parasagittal areas. Several months later, 
in November 2017 second cranial CT examination 
detected progression of the infiltrative process as two 
zones of osteolytic changes, affecting the tabula 
externa and the diploe of tabula interna (Figure 1d - 
1f). 
Complete excision with removal of periosteum 
and partial removal of the tabula externa was 
performed in collaboration with the neurosurgical team 
(Figure 2a, 2b). Intraoperative findings showed tumour 
infiltration of the parietal bone and the superficial layer 
of dura mater. This neoplastic formation was 
surgically removed in maximal safety margins. 
Thermal ablation of dura mater was performed as the 
tabula interna remained intact (Figure 2c - 2e). 
Hydroxyapatite cement was used for reconstruction of 
the cranial bone defect (Figure 2f - 2g). After 
meticulous haemostasis and layered soft tissue 
suturing, the surgical wound was covered with a 
sterile Bactrigrass dressing. The patient was referred 
to the plastic surgery department for reconstruction of 
the skin defect. 
 
Figure 2: a) Careful dissection of the skin around the tumor with a wide 
margin of surgical safety; b) Skin defect as a result from complete dissection 
of the skin around the area of the tumors; c) In the 4 corners of а provisional 
rectangle surrounding the tumors 4 defects are situated via high-frequency 
drill with a set of specific heads. Dura mater remains intact. Severe bleeding 
was stopped with an electric knife; d) Clinical finding after locating of 
additional bone defects in the calvarium region; e) Careful removal of the 
cranial parts infiltrated by a tumour as well as part of dura mater with 
neoplastic involvement. Haemostasis; f) Applying hydroxyapatite bone 
cement for reconstruction of the cranial defect; g) Precise adaptation of the 
cement before hardening; h) Layered soft tissue closure after the surgical 
removal of the lesions; i) Postoperative status after adaptation 
 
Histological examination revealed basal cell 
carcinoma invasion with clear surgical margins. 
 
Figure 3: 3а – Histopathological data of basal cell carcinoma 
infiltrating the bone. Unsuccessful pathologic sample; 3b – Routine 
postoperative CT-imaging of the patient is showing relatively good 
adaptation of the cement to the normal cranial structure; 3c – Early 
postoperative CT of the patient. Inapparent finding. CT 3 days after 
surgical approach with cranial bone resection because of 
postoperatively reduced sensitivity of the right part of the body, 
suspected for ischemic insult 
 
Case Report 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
374                                                                                                                                                                                                https://www.id-press.eu/mjms/index 
 
Discussion  
 
We present to the dermatological and 
oncosurgical community a clinical case of a patient 
with basal cell carcinoma who developed recurrent 
neoplastic lesions with the progressive invasion of the 
skull due to incorrect treatment. The main principle for 
treatment of any malignant lesions including BCC is 
radical surgical elimination insufficient field of surgical 
safety [7]. 
As it is stated in the National Comprehensive 
Cancer Network (NCCN), the aim of treatment for 
BCC is the elimination of a tumour with maximal 
preservation of function and physical appearance [8]. 
The therapeutic strategy should be individualised to 
every patient according to the size, location and depth 
of a tumour as well as comorbidity and additional 
examination findings [9]. However, in any case, there 
is a simple rule of great importance that should always 
be followed when it refers to surgical management, 
and it is the definitive requirement of radical surgical 
approach. Any ignorance of this principle is a potential 
triggering factor for neoplastic development [10]. For 
this particular reason in most cases radical surgical 
excision with histopathological evaluation and regular 
dermatological follow up is the first line treatment for 
BCC [11]. In cases of more difficult to treat lesions, 
Mohs micrographic surgery is considered an eligible 
and reasonable option [12]. 
There are various alternative non - surgical 
methods for the treatment of BCC [13]. Radiation 
therapy is a standard therapeutic option for patients 
with contraindications for surgery, but it can also be 
used as adjuvant therapy [14]. However, according to 
the Guideline recommendations on BCC, it is not 
recommendable as first-line treatment if surgical 
excision is possible [15]. Curettage and cautery, as 
well as cryosurgery and laser ablative therapy, show 
variable recurrence rates and may be considered as a 
good treatment only for low-risk BCC [16]. Local 
therapy with chemotherapeutic and immune -
modulating agents such as topical Imiquimod 5% or 
Fluorouracil may be indicated in some cases of small 
and superficial BCC [17]. Topical photodynamic 
therapy is another option, appropriate for superficial 
and thin nodular BCC in patients with large or multiple 
lesions and those in sites of high cosmetic importance 
[18].  
A Hedgehog (Hh) pathway inhibitor 
(Vismodegib, Sonidegib) can be used for locally 
advanced BCC in patients with contraindications for 
surgical or radiation therapy as well as for post-
treatment recidives and metastatic forms of BCC [19]. 
Unfortunately, according to the anamnestic 
data of our patient it can be concluded either that he 
had been treated several times with an inadequate 
treatment modality or that the electrocauterisation was 
not performed in enough margins. 
Although BCC in the area of the head is 
commonly seen, the risk of involvement of the skull 
and dura mater is extremely rare with an estimated 
incidence of 0.03% [20]. According to a PubMed 
search, there are only 13 cases of BCC of the scalp 
with intracranial tumour invasion described in the 
world literature till now. Local excision of the scalp in 
combination with craniectomy with dural resection (if 
needed) is the standard surgical treatment in such 
cases [21]. It is followed by reconstruction of the bone 
defects (cranioplasty) using fascial graft for dura 
mater, and bone cement (calcium hydroxyapatite) and 
titanium mesh for the skull [22]. Skin and soft tissue 
defects are reconstructed using island flaps, rotational 
flaps or free tissue transfer [23][24]. Depending on the 
depth of tumour invasion, curettage of the tabula 
externa is a less traumatic therapeutic option which 
does not need any further osteoplasty. It is indicated 
in limited cases where the tumour process has 
superficial spreading and evolves only part of the 
cranium’s thickness [25]. Both surgical techniques 
require clear surgical bone margins [26]. Surgical 
management of BCC is a serious challenge for the 
operating team in cases of neglected patients or 
histopathological subtypes of BCC with aggressive 
behaviour, represented as rapid growth into large 
sizes [27]. 
It is important to keep in mind that an 
infiltrative tumour process can be inapparent for a 
long time which reaffirms that every lesion should not 
be evaluated but removed concerning all principles of 
the good oncosurgical practice [28]. Precisely 
managed therapy of BCC is curative in most of the 
cases as it ensures good prognosis for the patient 
[29]. However, it shows high recurrence rate with risk 
of extensive invasion if there is not complete surgical 
removal [30].  
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